# **Special Issue**

## Immune Responses to Papillomavirus Infections: 2nd Edition

### Message from the Guest Editor

Human papillomavirus (HPV) infection is the most common sexually transmitted disease that causes approximately 5% of human cancers. Current prophylactic vaccines are effective at preventing HPV infections but provide no therapeutic effect on preexisting HPV infections. Intriguingly, most HPV (about 90%) infections are cleared by hosts within 1–2 years after exposure. Understanding host control of HPV infections will potentially shed light on the development of novel therapy for HPV-associated diseases and cancers. In view of the success of the first volume (https://www.mdpi.com/journal/viruses/special\_issues/2) 2667S4AC9) and the continued interest it generated, we plan to reopen this second volume. The current issue still covers research relating to how the immune system effectively clears papillomavirus infections, and what immune responses are key factors in this optimum outcome. We would like to invite you to share your recent findings or perspectives on host immunity to papillomavirus, including but not limited to innate and adaptive immune responses in preclinical models and human studies.

### **Guest Editor**

Dr. Jiafen Hu

Department of Pathology, Pennsylvania State University College of Medicine, Hershey, PA 17033, USA

### Deadline for manuscript submissions

30 June 2026



## **Viruses**

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/216321

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/ viruses





## Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



### **About the Journal**

### Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Viruses* (ISSN 1999-4915). *Viruses* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. As an open access journal, *Viruses* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. We would be pleased to welcome you as one of our authors.

### **Editor-in-Chief**

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

#### **Author Benefits**

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

### **Journal Rank:**

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).

